stockrowVertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
Follow VRTX
Alert me
Vertex Pharmaceuticals Incorporated (VRTX) Total debt
Vertex Pharmaceuticals Incorporated's total debt at the end of fiscal 2024 was $112.8M, down 70.0% from $376.1M in fiscal 2023. At the end of the quarter to 30 September 2026 it was $3.5B. Over the past ten years it has ranged from $112.8M (fiscal 2024) to $821.3M (fiscal 2016) — the current reading is the lowest in ten years. Vertex Pharmaceuticals Incorporated ranks 5th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2024 | $112.8M | (70.01%) |
| FY2023 | $376.1M | (12.70%) |
| FY2022 | $430.8M | (15.50%) |
| FY2021 | $509.8M | (5.42%) |
| FY2020 | $539.0M | 0.08% |
| FY2019 | $538.6M | (7.39%) |
| FY2018 | $581.6M | (0.40%) |
| FY2017 | $583.9M | (28.91%) |
| FY2016 | $821.3M | 1.31% |
| FY2015 | $810.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $3.5B | 3,039.14% |
| Mar 2025 | $111.4M | (1.24%) |
| Dec 2024 | $112.8M | (1.05%) |
| Sep 2024 | $114.0M | (67.11%) |
| 38 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $8.6B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| VRTX Vertex Pharmaceuticals Incorporated | $3.5B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $2.0B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $825.2M |
| MRNA Moderna, Inc. compare | $597.0M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement